{"database": "openregs", "table": "dockets", "rows": [["FDA-2025-P-4151", "FDA", "Requests that FDA determine whether ReVia (naltrexone HCl) Tablets, 50 mg, approved under New Drug Application (NDA) number 018932, held by Teva Women\u2019s Health, Inc., has been voluntarily withdrawn for reasons of safety or effectiveness", "Nonrulemaking", "2026-04-21T12:49:27Z", "0b000064b8fd6fe0"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2025-P-4151"], "units": {}, "query_ms": 1.096392996259965, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}